Moderna Crecimiento futuro

Future controles de criterios 0/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Moderna de 58.6% y 14.4% por año respectivamente. Se prevé que el BPA crezca en un 61.5% al año. Se espera que la rentabilidad financiera sea de -6.7% en 3 años.

Información clave

58.6%

Tasa de crecimiento de los beneficios

61.5%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	0%
Tasa de crecimiento de los ingresos	14.4%
Rentabilidad financiera futura	-6.7%
Cobertura de analistas	Good
Última actualización	01 Mar 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Previsiones de crecimiento de beneficios e ingresos

BUL:0QF - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	6,598	-491	-200	-126	13
12/31/2025	4,967	-1,904	-1,698	-1,264	23
12/31/2024	4,246	-2,767	-2,306	-1,648	24
12/31/2023	6,848	-4,714	-3,825	-3,118	N/A
9/30/2023	9,121	-3,466	-2,657	-2,078	N/A
6/30/2023	10,654	1,207	-754	-226	N/A
3/31/2023	15,059	4,784	612	993	N/A
12/31/2022	19,263	8,362	4,581	4,981	N/A
9/30/2022	21,390	11,765	6,201	6,629	N/A
6/30/2022	22,995	14,055	9,215	9,653	N/A
3/31/2022	22,600	14,638	13,031	13,412	N/A
12/31/2021	18,471	12,202	13,336	13,620	N/A
9/30/2021	11,831	7,061	11,386	11,574	N/A
6/30/2021	7,019	3,495	9,083	9,191	N/A
3/31/2021	2,732	598	5,007	5,104	N/A
12/31/2020	803	-747	1,959	2,027	N/A
9/30/2020	246	-597	613	664	N/A
6/30/2020	106	-488	-374	-336	N/A
3/31/2020	52	-505	-451	-421	N/A
12/31/2019	60	-514	-491	-459	N/A
9/30/2019	82	-535	-489	-451	N/A
6/30/2019	106	-499	-482	-424	N/A
3/31/2019	122	-459	-445	-364	N/A
12/31/2018	135	-402	-437	-331	N/A
9/30/2018	192	-299	-447	-343	N/A
6/30/2018	192	-280	-412	-305	N/A
3/31/2018	199	-266	-432	-350	N/A
12/31/2017	206	-270	-390	-331	N/A
12/31/2016	108	-230	N/A	67	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que 0QF siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que 0QF siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que 0QF siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (14.4% al año) de 0QF crezcan más despacio que el mercado de BG (4.8% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 14.4% al año) de 0QF crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: 0QF se prevé que no sea rentable en 3 años.

Moderna Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Moderna, Inc. Reiterates Earnings Guidance for the Year 2024, 2025 and 2026

Moderna, Inc. Provides Sales Guidance for the Year 2023

Moderna, Inc. Provides Sales Guidance for the Full Year 2023

Recent updates

Moderna, Inc. to Report Q1, 2024 Results on May 02, 2024

Arbutus Biopharma Announces Claim Construction Ruling in Its Ongoing Patent Infringement Lawsuit Against Moderna

Moderna, Inc. Advances Multiple Vaccine Programs to Late-Stage Clinical Trials

Moderna, Inc. Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine

Moderna, Inc., Annual General Meeting, May 06, 2024

Moderna, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Moderna, Inc. Reiterates Earnings Guidance for the Year 2024, 2025 and 2026

Moderna Announces Changes to Commercial Organization

Moderna Announces Changes to Commercial Organization

Moderna, Inc. Provides Sales Guidance for the Year 2023

Third quarter 2023 earnings released: US$9.53 loss per share (vs US$2.67 profit in 3Q 2022)

Moderna Announces First Participant Dosed in Phase 3 Study of mRNA-1083, a Combination Vaccine against Influenza and COVID-19

Moderna, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Moderna, Inc. Announces Positive Phase 1/2 Data from mRNA-1083, the company's Combination Vaccine Against Influenza and COVID-19

Moderna, Inc. Announces Ema Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's Updated Covid-19 Vaccine in the European Union

Moderna Receives U.S. FDA Approval for Updated Covid-19 Vaccine

Moderna Clinical Trial Data Confirm Its Updated Covid-19 Vaccine Generates Strong Immune Response in Humans Against Ba.2.86

Moderna Clinical Trial Data Confirm its Updated COVID-19 Vaccine Generates Robust Immune Response in Humans Against Widely Circulating Variants

UMass Chan Medical School Announces Enrollment in Study to Explore Impact of Cytomegalovirus (CMV) Transmission in Early Education Settings

New minor risk - Profit margin trend

Second quarter 2023 earnings released: US$3.62 loss per share (vs US$5.55 profit in 2Q 2022)

Moderna, Inc. Provides Sales Guidance for the Full Year 2023

Merck and Moderna, Inc. Initiate Phase 3 Study Evaluating V940 (Mrna-4157) in Combination with Keytruda(R) (Pembrolizumab) for Adjuvant Treatment of Patients with Resected High-Risk (Stage Iib-Iv) Melanoma

Moderna, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Moderna Announces Global Regulatory Submissions for its Respiratory Syncytial Virus (RSV) Vaccine, mRNA-1345

Moderna, Inc. Submits Regulatory Application to the European Medicines Agency for Its Updated COVID-19 Vaccine

Moderna, Inc.(NasdaqGS:MRNA) dropped from Russell Top 200 Growth Index

Moderna, Inc. Completes Submission of A Regulatory Application to the U.S. Food and Drug Administration for Its Updated COVID-19 Vaccine Containing Spike Proteins for the XBB.1.5 Sublineage of SARS-CoV-2

Moderna and Merck Announces mRNA-4157 (V940) in Combination With KEYTRUDA Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection Versus KEYTRUDA

Moderna, Inc. Announces Interim Phase 3 Safety and Immunogenicity Results for mRNA-1010, A Seasonal Influenza Vaccine Candidate

Moderna, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Moderna Granted FDA Breakthrough Therapy Designation for mRNA-1345, an Investigational Respiratory Syncytial Virus (RSV) Vaccine Candidate

Moderna Announces mRNA-1345, an Investigational Respiratory Syncytial Virus (RSV) Vaccine, Has Met Primary Efficacy Endpoints in Phase 3 Trial in Older Adults

Moderna, Inc. (NasdaqGS:MRNA) entered into a definitive agreement to acquire OriCiro Genomics, Inc for $85 million.

Chantal Friebertshäuser Joins Moderna, Inc. as Senior Vice President of Commercial - Europe, Middle East and Canada, Effective January 1, 2023

Moderna, Inc. and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial

Moderna Receives FDA Emergency Use Authorization for Omicron-Targeting Bivalent COVID-19 Booster Vaccine in Children 6 Months Through 5 Years of Age

Moderna, Inc. Announces Executive Changes

Moderna's BA.4/BA.5 Targeting Bivalent Booster, mRNA-1273.222, Meets Primary Endpoint of Superiority Against Omicron Variants Compared to Booster Dose of mRNA-1273 in Phase 2/3 Clinical Trial

Moderna, Inc. Receives Health Canada Authorization for Second Omicron-Targeting Bivalent Booster

Ministry of Health, Labour and Welfare in Japan Approves Partial Change to a New Drug Authorization for Moderna's Omicron-Targeting Bivalent Booster COVID-19 Vaccine, mRNA-1273.222

Moderna, Inc. Announces EMA Committee for Medicinal Products for Human Use Issues Positive Opinion Recommending Authorization for the Use of Spikevax (mRNA-1273) in Children 6 Months - 5 Years in the European Union

Moderna, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Moderna, Inc. Receives FDA Authorization for Emergency Use of Omicron-Targeting Bivalent COVID-19 Booster Vaccine for Children and Adolescents 6 to 17 Years of Age

Moderna, Inc. Announces Management Changes

European Medicines Agency Accepts Moderna's Conditional Marketing Authorization Filing for its Omicron BA.4/BA.5 Targeting Bivalent COVID-19 Vaccine

Ministry Of Health, Labour and Welfare in Japan Approves Partial Change to a New Drug Authorization for Moderna's Omicron-Targeting Bivalent Booster COVID-19 Vaccine, mRNA-1273.214

Moderna Reviews Clinical Trial Programs Across Portfolio at 2022 R&D Day

EMA Committee for Medicinal Products for Human Use (Chmp) Adopts Positive Opinion Recommending Authorization for the Use of Moderna's Omicron-Targeting Bivalent Booster in the European Union

Moderna, Inc. Announces Swissmedic Authorizes its Omicron-Targeting Bivalent Booster Candidate, MRNA-1273.214

Moderna, Inc. Announces Executive Changes

Moderna, Inc. Announces Medicines and Healthcare Products Regulatory Agency Authorizes Omicron-Containing Bivalent Booster in the Uk

Moderna, Inc. Fires Jorge Gomez as CFO

Moderna, Inc. Appoints Arpa Garay as Chief Commercial Officer, Effective May 31, 2022

Moderna, Inc. to Report Q1, 2022 Results on May 04, 2022

Moderna, Inc. Announces Executive Changes

Genevant Sciences and Arbutus Biopharma File Patent Infringement Lawsuit Against Moderna

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento